# A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-phase-iii-adjuvant-vinorelbine-plus-cisplatin-np-versus-np-plus-endostar-npe/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jie Hu,Z. Xiangru,Baohui Han,Ye Liu,Q. Wang,Shanlin Xu,Yaping Sheng,Q. Li,Szu‐Yuan Wu,C. Chen |
| Citations | 1 |
| DOI | 10.1200/jco.2010.28.15_suppl.7019 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2244923448 |
| Type | conference-abstract |
| Year | 2010 |

## Paper authors

- [Ye Liu](https://scholariq.org/researchers/ye-liu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.